

PROVINCIAL FUNDING SUMMARY

Carfilzomib (Kyprolis) for Multiple Myeloma (relapsed) (pCODR 10084)

pERC Recommendation: Recommends

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: April 17, 2017

This information is current as of February 6, 2019.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	Apr 1, 2018	<p>A) Carfilzomib/Dexamethasone: For the treatment of multiple myeloma in patients who received at least one prior therapy. Physician may add cyclophosphamide to increase response.</p> <ul style="list-style-type: none"> Life expectancy of greater than 3 months A BC Cancer “Compassionate Access Program” request with appropriate clinical information for each patient must be approved prior to treatment. <p>B) Carfilzomib/Lenalidomide/Dexamethasone For the treatment of multiple myeloma in patients who received at least one prior therapy.</p> <ul style="list-style-type: none"> Patients must be sensitive to lenalidomide and bortezomib or not previously exposed. Life expectancy of greater than 3 months A BC Cancer “Compassionate Access Program” request with appropriate clinical information for each patient must be approved prior to treatment Registration of the prescribing physician and patient with the RevAid Program (www.RevAid.ca)
AB	Funded	Oct 30, 2018	In combination with dexamethasone for patients with relapsed multiple myeloma with a good performance status who have received one to three previous therapies May be used following daratumumab triplet therapy.
SK	Funded	Aug 15, 2018	In combination with Dexamethasone (Kd regimen) for patients with relapsed multiple myeloma with a good performance status who have received one to three prior treatments, and whose disease is refractory to either Lenalidomide or Bortezomib or both.
MB	Funded	Mar 9, 2018	Carfilzomib in combination with dexamethasone (Kd regimen) for patients with relapsed multiple myeloma with a good performance status who received one to three prior treatments.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
ON	Funded	May 1, 2018	Carfilzomib in combination with dexamethasone for patients with relapsed multiple myeloma with a good performance status who received 1 to 3 prior treatments.
NS	Funded	Oct 15, 2018	In combination with dexamethasone for patients with relapsed multiple myeloma with a good performance status who have received at least one prior treatment. Treatment with Carfilzomib should continue until disease progression or unacceptable toxicity.
NB	Funded	Sept 27, 2018	In combination with dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior treatments. Patients must have a good performance status. Treatment with carfilzomib should be discontinued upon disease progression or unacceptable toxicity.
NL	Funded	July 3, 2018	In combination with dexamethasone for patients with relapsed multiple myeloma with a good performance status who received one to three prior treatments.
PEI	Under provincial consideration		

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.